Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage
1 Institute of Social and Family Medicine, School of Public Health, Zhejiang University, Hangzhou 310058, China
2 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
3 Cancer Registry of Rhineland-Palatinate, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
4 Saarland Cancer Registry, Saarbrücken, Germany
5 Institute for Clinical Epidemiology, Cancer Registry of Schleswig-Holstein, University of Lübeck, Lübeck, Germany
6 Institute of Social and Family Medicine, School of Medicine (Post box 25#), Zhejiang University, Yuhangtang Road 866, Hangzhou 310058, Zhejiang Province, China
7 Members of the GEKID Cancer Survival Working Group are listed in the acknowledgements
BMC Cancer 2012, 12:128 doi:10.1186/1471-2407-12-128Published: 30 March 2012
Population-based studies on endometrial cancer providing survival estimates by age, histology, and stage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for endometrial cancer patients in Germany.
We used a pooled German national dataset including data from 11 cancer registries covering a population of 33 million people. 30,906 patients diagnosed with endometrial cancer in 1997-2006 were included. Period analysis was performed to calculate 5-year relative survival (RS) in 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age-adjustment was performed using five age groups (15-44, 45-54, 55-64, 65-74, and 75+ years).
Overall, age-adjusted 5-year relative survival in 2002-2006 was 81%. A moderate age gradient was observed, with 5-year RS decreasing from 90% in the age group 15-49 years to 75% in the age group 70+ years. Furthermore prognosis varied strongly by histologic subtypes and stage, with age-adjusted 5-year RS ranging from 43% (for sarcoma) to 94% (for squamous metaplasia), and reaching 91% for localized, 51% for regional, and 20% for distant stage. Except for age group 65-74 years, no significant improvement in survival was seen during the recent 5-year period under investigation.
In this comprehensive population-based survival analysis of patients with endometrial cancer from Germany, prognosis of endometrial cancer moderately varied by age, and strongly varied by histology and stage. While prognosis is rather good overall, further improvement in 5-year relative survival of endometrial cancer patients has been stagnating in the early 21st century.